Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use?

Area of Science:

• Pediatric Hematology
• Clinical Nutrition
• Pharmacology

Background:

• Recombinant human erythropoietin (EPO) therapy efficacy is significantly limited by iron deficiency.
• Identifying and monitoring children at risk for iron deficiency during EPO treatment is critical for optimal outcomes.

Purpose of the Study:

• To determine the best methods for identifying and monitoring iron deficiency in children receiving EPO therapy.
• To assess the relationship between iron status parameters and EPO treatment response.

Main Methods:

• Serial measurement of iron status parameters in nine children before and during a 24-week EPO therapy period.
• Evaluation of serum ferritin, hemoglobin, and red cell indices (MCV, hypochromia, microcytosis) as predictors of iron deficiency.
• Assessment of iron treatment efficacy on hemoglobin and iron status.

Main Results:

• Serum ferritin ≤60 µg/L at baseline was the best predictor of developing iron deficiency during EPO therapy.
• Five of nine children developed iron deficiency, evidenced by poor hemoglobin response and microcytosis/hypochromia.
• A falling mean red cell volume (MCV) correlated with a poor EPO response. Iron supplementation improved hemoglobin and iron status, though MCV remained low.

Conclusions:

• Children with serum ferritin ≤60 µg/L or a falling MCV during EPO treatment should receive high-dose oral iron supplementation.
• Proactive iron management is essential for maximizing the therapeutic benefits of EPO in pediatric populations.
• Increased red cell volume distribution width after iron therapy may indicate a positive response to iron supplementation.